XML 15 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2018
Dec. 31, 2017
Current assets    
Cash and cash equivalents, including restricted cash of $200 $ 6,315 $ 4,219
Accounts receivable, net 1,731 1,529
Inventories 2,524 2,249
Prepaid expenses and other current assets 1,114 714
Note receivable, current portion 95
Total current assets 11,684 8,806
Property, plant and equipment, net 6,061 6,215
Intangible assets, net 2,964 2,860
Note receivable, less current portion 302
Goodwill 2,227 2,227
TOTAL ASSETS 28,289 23,917
Current liabilities    
Accounts payable and accrued expenses 5,931 3,885
Accrued payroll and related liabilities 1,727 1,209
Deferred revenue and customer deposits 98 29
Current portion of deferred acquisition obligation and accrued interest 53
Current portion of note payable, net of unamortized debt discount 1,729
Current portion of capital lease obligations, net of unamortized discount 883 598
Total current liabilities 10,368 5,774
Capital lease obligations, net of current portion and unamortized discount 720
Accrued expenses, net of current portion 800 800
Note payable, net of current portion and unamortized debt discount 12,668 14,008
TOTAL LIABILITIES 23,836 21,302
STOCKHOLDERS' EQUITY    
Common stock, $0.001 par value, 90,000,000 shares authorized, 22,656,183 and 20,623,129 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively 23 21
Additional paid-in capital 96,771 91,430
Accumulated deficit (92,341) (88,836)
TOTAL STOCKHOLDERS' EQUITY 4,453 2,615
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY 28,289 23,917
Surface Pharmaceuticals [Member]    
Current assets    
Investment 5,090
Eton Pharmaceuticals [Member]    
Current assets    
Investment $ 263 $ 3,507